Patent ID: 7794705

Claim:
A sterile pharmaceutical composition for repairing a vascular injury in a subject in need thereof, wherein the vascular injury is an acute myocardial infarction resulting from underlying diseases and the subject is a revascularized subject, the sterile pharmaceutical composition comprising: (a) a therapeutically effective amount of a sterile chemotactic hematopoietic stem cell product, the chemotactic hematopoietic stem cell product comprising a nonexpanded, isolated population of autologous mononuclear cells enriched for CD34+ cells, which further contains a subpopulation of potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity; and (b) a stabilizing amount of serum, wherein the stabilizing amount of serum is greater than 20% (v/v), wherein the pharmaceutical composition is further characterized as having the following properties for at least 24 hours following acquisition of the chemotactic hematopoietic stem cell product when tested in vitro after passage through a catheter: (i) at least 70% of the cells are CD34+ cells; (ii) contains a subpopulation of potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity; (iii) is at least 70% viable; and (iv) is able to form hematopoietic colonies in vitro.